title: Effects of estradiol and estradiol sulfamate on the uterus of ovariectomized or ovariectomized and hypophysectomized rats.
abstract: Estradiol sulfamate (J995), estradiol-17beta with a substituted sulfamate group in position 3, has much higher systemic estrogenic activity after oral administration than 17beta-estradiol (E2) due to reduced hepatic metabolism of the drug. The lower dose necessary for achievement of adequate systemic estrogenic effects results in a substantial reduction of otherwise commonly observed hepatic side-effects. This makes J995 a strong candidate as an estrogen suitable for oral administration. The present study was performed to examine and compare the effects of J995 and E2 on the uterus after oral or subcutaneous administration to ovariectomized or ovariectomized+hypophysectomized female rats, in particular on the levels of the estrogen receptor (ER) (alpha+beta), ERalpha mRNA and insulin-like growth factor-I (IGF-I) mRNA. The ER levels were determined using a ligand binding assay and the mRNA levels using solution hybridization. The doses of J995 or E2 were chosen to achieve comparable uterotrophic activity. The rats were treated with hormones for 7 days and the treatment was initiated 14 days after surgery. We conclude that there are no major differences in the uterine response to treatment with J995 or E2 with respect to the effects on ER and ERalpha mRNA levels. The IGF-I mRNA level though, is more affected by J995 than by E2 after 7 days of treatment, indicating a prolonged effect of J995.
authors.affiliation: Division for Reproductive Endocrinology, Department of Woman and Child Health, Karolinska Hospital, L5:01, S-171 76, Stockholm, Sweden. lena.sahlin@kbh.ki.se
authors.forename: L
authors.initials: L
authors.lastname: Sahlin
authors.forename: W
authors.initials: W
authors.lastname: Elger
authors.forename: S
authors.initials: S
authors.lastname: Akerberg
authors.forename: B
authors.initials: B
authors.lastname: Masironi
authors.forename: G
authors.initials: G
authors.lastname: Reddersen
authors.forename: B
authors.initials: B
authors.lastname: Schneider
authors.forename: S
authors.initials: S
authors.lastname: Schwarz
authors.forename: B
authors.initials: B
authors.lastname: Freyschuss
authors.forename: H
authors.initials: H
authors.lastname: Eriksson
mesh_terms: D000284:Administration, Oral; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000097:blood / Q000737:chemistry / Q000494:pharmacology*; D047628:Estrogen Receptor alpha; D005260:Female; D007016:Hypophysectomy; D007279:Injections, Subcutaneous; D007334:Insulin-Like Growth Factor I / Q000235:genetics; D009929:Organ Size / Q000187:drug effects; D010052:Ovariectomy; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D011863:Radioimmunoassay; D051381:Rats; D017208:Rats, Wistar; D011960:Receptors, Estrogen / Q000235:genetics / Q000378:metabolism; D013449:Sulfonamides / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D014599:Uterus / Q000187:drug effects* / Q000378:metabolism
chemical_list: C119805:17-benzylestradiol 3-O-sulfamate; D047628:Estrogen Receptor alpha; D012333:RNA, Messenger; D011960:Receptors, Estrogen; D013449:Sulfonamides; D004958:Estradiol; D007334:Insulin-Like Growth Factor I